(M) Apheresis Flashcards

1
Q

It is a procedure in which whole blood is taken from the body and passed through an apparatus that separates out one or more constituents, then returns the remainder of constituents back to the body circulation.

A

Apheresis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Apheresis comes from the Greek term “aphairesis” meaning ____

A

taking away

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Performed on a donor to collect a SPECIFIC blood component (e.g. Red blood cells, Plasma, Platelets, Stem cells, etc.), needs to be a healthy donor

A

donor apheresis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Performed on a patient to remove a PARTICULAR blood component for ____
- Removing antibodies in autoimmune disorders
- Removing excess ions on hemochromatosis
- Treating a sickle cell disease by removing the Red blood cell

A

therapeutic apheresis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the three components collected through apheresis?

A
  1. platelets
  2. RBCs
  3. Stem cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Process of removing apheresis

  1. removing of plasma =
  2. removing platelets =
  3. removing red blood cells =
  4. removal of white blood cells =
A
  1. plasmapheresis
  2. plateletpheresis
  3. erythropheresis
  4. leukapheresis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Identify the blood component:

  1. 55% of the blood volume
  2. 1% of the blood volume
  3. 45% of the blood volume
A
  1. plasma
  2. buffy coat
  3. red blood cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Identify the percentage in the plasma composisiton

  1. water
  2. proteins
  3. other solutes
A
  1. 91.5%
  2. 7%
  3. 1.5%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

primary anticoagulant in apheresis

A

citrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Citrate

Works by binding two ____ ions, preventing blood clotting

A

calcium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Released in response to decreased ionized calcium level.
It will help regulate calcium levels by stimulating the release of calcium from the bones and increasing the calcium reabsorption in the kidneys

A

Parathyroid hormone (PTH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Methodology

  1. separatese the blood components based on their density
  2. Separates the blood components based on size and molecular weight.
A
  1. centrifugation
  2. membrane filtration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Centrifugation

  1. The separation of blood components is based on blood constituents’ ____ or ____.
  2. Duration of procedure: _____
A
  1. The separation of blood components is based on blood constituents’ specific gravity or weight.
  2. 45 to 120 minutes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Variables considered in apheresis procedure

  1. centrifuge ____ and ____
  2. Duration of ____ of the blood in the centrifuge
  3. Type of solutions added
  4. Cellular ____ or plasma ____
A
  1. centrifuge speed and diameter
  2. Duration of dwell time of the blood in the centrifuge
  3. Type of solutions added
  4. Cellular content or plasma volume
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

T or F

  1. The higher the centrifuge speed the better the separation, thus higher speeds are usually used for apheresis.
  2. Shorter dwell times have no risk for cell damage or activation
  3. EDTA is the anticoagulants of choice for apheresis
  4. Citrate or heparin can be added to enhance for sedimenting agents (hydroxyethyl strach) to enhance the separation of blood components
A
  1. False (Really high speeds are not advisable because they pose a risk for cell damage)
  2. True (longer dwell times are better for separation but has a risk for cell damage)
  3. False (citrate or heparin)
  4. True
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

A. Intermittent Flow Centrifugation (IFC)
B. Continuous Flow Centrifugation (CFC)

  1. Blood is processed in batches or cycles
  2. Performed as a single-needle procedure
  3. Blood withdrawal, processing and reinfusion are performed in an ongoing manner
  4. Dual-lumen central venous catheter can be used in therapeuitic procedures
  5. Two venipuncture sites are needed
A
  1. A
  2. A
  3. B
  4. B
  5. B
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

A. Intermittent Flow Centrifugation (IFC)
B. Continuous Flow Centrifugation (CFC)

  1. Greater blood volume is needed
  2. Smaller blood volumes (for pediatrics and elderly)
  3. Lesser time of collection
  4. Smaller equipment, more mobile
  5. Longer duration (fixed speed)
  6. Causes discomfort
A
  1. A
  2. B
  3. B
  4. A
  5. A
  6. B
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q
  • composed of bundles of hollow fibers or flat plate membranes with specific pore sizes.
  • The pore size of the membrane determines the type of component that can pass through
  • It is used only for plasma collection
A

Membrane filtration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the pore size used in membrane filtration

A

0.2 to 0.5 micrometers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q
  • The instrument combines centrifugation and membrane filtration technology by using a small rotating cylindrical filter.
  • The instrument uses a dual-stage process, with centrifugation as the initial separation and membrane filtration for further purification.
A

Fenwal autopheresis-C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Donation frequency

2RBC

A

16 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Donation frequency

Plasma (frequent)

A

Every 2 days, no more than 2 times in 7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Donation frequency

Plasma (Infrequent)

A

Every 4 weeks (no more than 13 times/year)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Donation frequency

Platelets, single apheresis unit

A

Every 2 days (no more than 2 times in 7 dyas; no more than 24 times in 12 months)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Donation frequency

Platelets, double or triple apheresis unit

A

every 7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Donation Frequency

Granulocytes

A

Every 2 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

T or F: Donation frequency will vary based on red cell gain and if more than one type of component is collected concurrently.

A

F (red cell loss)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Enumerate the nine (9) requirements for an apheresis program unit.

A
  1. Qualified licensed physician
  2. Good equipment
  3. Well-trained and motivated staff
  4. Written form consent
  5. Standardized protocols and policies for component collection and therapeutic procedure
  6. QC of equipment and apheresis product
  7. Management of adverse reactions
  8. Post-apheresis care
  9. Proper record-keeping and documentation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are the four (4) components under apheresis?

A
  1. RBCs
  2. Plasma
  3. Platelets
  4. Granulocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q
  • Typically collected as a double unit
A

RBCs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

RBCs Component Collection

This is the clinical advantage of collecting apheresis RBCs

A

Reduced donor exposure for recepient (since RBCs are collected as double units)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

RBCs Component Collection

The hematocrit must be at least ____ regardless of the gender.

A

40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

RBCs Component Collection

It should be determined by (qualitative/quantitative) method

A

Quantitative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

RBCs Component Collection

T or F: The use of copper sulfate is acceptable.

A

F

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Component collection

  • It can be used to augment the inventory of fresh frozen
    plasma (FFP) of a particular ABO group, especially group
    AB.
  • for direct patient use
A

PLASMA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Component collection: Plasma

  1. What ABO type is considered to be the universal donor?
  2. What is the maximum allowable volume donated per year according to the FDA guidelines?
A
  1. AB
  2. 12L or 14.4L (for donors >175 lbs)
37
Q

Component collection

  1. Platelet obtained by apheresis provides the equivalent of ____ units of whole blood - derived platelets (random-donor platelets), significantly decreasing a patient’s donor exposure.
  2. The platelets are suspended in ____ in a collection bag specificallly designed for platelet storage
A
  1. Platelet obtained by apheresis provides the equivalent of 6 to 8 units of whole blood - derived platelets (random-donor platelets), significantly decreasing a patient’s donor exposure.
  2. The platelets are suspended in donor plasma in a collection bag specificallly designed for platelet storage
38
Q

Component collection: platelets

  1. A platelet procedure usually takes ____ minutes
  2. The interval between plateletpheresis procedures must be at least ____ days with no more than two procedures in a ____ day period
A
  1. 45 to 90 minutes
  2. 2 days, 7 day period
39
Q

Component collection: platelets

  1. A donor may undergo no more than ____ plateletpheresis procedures in a rolling 12-month period
  2. The total plasma volum collected during any one procedure cannot exceed ____ mL or ____ mL (if donor weighs >175 lbs)
  3. What is the minimum platelet count required for a platelet donor?
A
  1. 24
  2. 500mL or 600mL
  3. 150,000/µL
40
Q

Antiplatelet medications deferral time

a. 48 hours
b. 14 days

  1. Aspirin
  2. Clopidogrel (Plavix)
  3. Ticlopidine (Ticlid)
  4. Aspirin-containing medications
41
Q

Antiplatelet medications deferral time

a. 48 hours
b. 14 days

  1. Ticagrelor (Brilinta)
  2. Anti-inflammatory drug Feldene
  3. Prasugrel (Effient)
42
Q

Component collection

  • beneficial to some severely neutropenic patients
  • has shown favorable results in treating neturopenic neonatees with sepsis
A

granulocytes

43
Q

Component collection

What is the minimum therapeutic dose of granulocytes?

A

1 × 10^10 granulocytes

44
Q

Component Collection: Granulocytes

Donors are stimulated with either a ____ or a ____ prior to the procedure and utilize a red blood cell sedimenting agent during the collection process

A
  1. corticosteroids or colony stimulating factor
45
Q

Component Collection: Granulocytes

What is the red blood cell sedimenting agent used?

A

Hydroxyethyl starch (HES)

46
Q

Therapeutic apheresis category according to the blood component removed

  1. procedure may be used to selectively remove RBCs, WBCs, or platelets.
  2. procedure is used to remove plasma when the pathological substance is found in the circulation.
A
  1. cytapheresis
  2. plasma pheresis
47
Q

INDICATION CATEGORIES FOR THERAPEUTIC APHERESIS

  1. Apheresis is standard and acceptable, either as primary therapy or as a first-line adjunct to other initial therapies.
  2. Apheresis is generally accepted in a supportive role or as second-line therapy, rather than first-line therapy
  3. Apheresis has been demonstrated to lack efficacy or be harmful and should be discouraged in these disorders. Clinical applications should be undertaken only under an approved research protocol.
  4. Apheresis is not clearly indicated based on insufficient evidence, conflicting results, or inability to document a favorable risk-to-benefit ratio. Decision-making should be individualized.
A
  1. Cattegory I
  2. Category II
  3. Category IV
  4. Category III
48
Q

The published guidelines by ____ is routinely updated but the decision should be individualized especially for Category III.

A

American Society for Apheresis

49
Q

What are the two (2) vascular consideration?

A
  1. Vascular Access
  2. Physiological Consideration
50
Q
  • Considered to ensure safe and effective treatment
A

Vascular Access

51
Q

Vascular Access

  • Most common access site
A

Peripheral Vein (arm)

52
Q

Vascular Access

  • Veins in the neck, chest or arm
A

Central Vein

53
Q

Vascular Access

T or F: Both the peripheral vein and central vain may be collected from either simultaneously or sequentially.

54
Q

Vascular Access

  • Mandatory during therapeutic apheresis as larger volumes of blood are processed and the duration of the procedure is longer than for donor apheresis
A

Adequate vascular access

55
Q

Vascular Access

What are the gauge/s used?

A

16 to 18 gauge needles

56
Q

Vascular Access

Poor vascular access may lead to what four (4) complications?

A
  1. Inadequate blood flow
  2. Hematoma formation
  3. Infection
  4. Nerve damage
57
Q

Physiological Considerations

Less than 15% of the total blood volume (TBV) to minimize risk of hypovolemia (low blood volume)

A

Extracorporeal Blood Volume

58
Q

What are the three (3) hypovolemia risks?

A
  1. Decreased blood pressure
  2. Reduced cardiac output
  3. Increase the risk of shock
59
Q

Physiological Considerations

Familiarize yourself with the prevention for the physiological considerations.

A
  1. Extracorporeal blood volume should be less than 15%
  2. Monitoring patient’s vital signs
  3. Adjust the procedure as needed
  4. Fluid intake to maintain the blood volume
60
Q

The removal and retention of the plasma, with return of all cellular components to the patient

A

Therapeutic Plasma Exchange

61
Q
  • Most common therapeutic apheresis procedure performed
  • Purpose: To remove agents in the plasma that is causing clinical conditions such as autoantibodies, immune complexes, toxins, and inflammatory mediators
  • Effectiveness relative to volume of plasma removed and concentration of pathological substance in the blood
A

Plasmapherisis

62
Q

Plasmapherisis

1 volume exchange = ?

A

approximately 3L

Reduce the unwanted plasma component to approximately 30%

63
Q
  • Used to treat patients who have abnormally elevated platelet counts
  • Platelet count will be decreased by 30% to 60%
  • The blood is extracted from the patient and is separated using centrifuge or membrane filtration to remove the excess platelets before the rest of the components are transfused back to the patient.
  • Can help reduce the risk of thrombotic and hemorrhagic complications
A

Plateletpheresis

64
Q

Match the following.

  1. Myeloproliferative disorders, polycythemia vera, essential thrombocythemia, CML, or as reactive process in response to splenectomy, infection, chronic inflammation, or malignancy
  2. The patient is at risk for developing thrombotic or hemorrhagic complication

A. 1,000,000/uL
B. 500,000/uL

65
Q
  • Reduces abnormally elevated leukocyte count
  • Used to treat patients with hyperleukocytosis, blast count of over 100,000/uL
  • A single procedure should reduce the WBC count by 30% to 60%
  • Reduces complications associated with hyperleukocytosis
A

Leukapheresis

66
Q

Leukapheresis

May be used to improve the separation of WBCs and other blood components

A

Hydroxyethyl Starch

67
Q
  • Removes large number of RBCs from the patient and returns the patient’s plasma and platelets
  • Performed in patients with sickle cell disease
  • Goal: To decrease the level of hemoglobin S to less than 30%
  • Treatment of overwhelming malaria or Babesia infections
  • Treating patients when the parasite load is greated than 10%
  • Removes incompatible RBCs from a patient’s circulation
A

Erythrocytapheresis

68
Q
  • Used to maintain fluid and electrolyte balance
  • Maintains blood volume to prevent hypotension
A

Fluid Replacement

69
Q

Fluid Replacement

The most common replacement fluid for TPE

A

Human Serum Albumin as a 5% solution

70
Q

Fluid Replacement

Replaces fluid in certain situations such as clotting factor replacement, thrombocytopenia purpura, hemolytic uremic syndrome

A

Fresh Frozen Plasma (FFP)

71
Q

Match the following.

  1. Systemic Lupus Erythematosus
  2. Guillain-Barre Syndrome, Goodpasture Syndrome
  3. Waldenstrom’s Macroglobulinemia
  4. Amanita Mushroom Poisoning, Barbiturate Poisoning
  5. Familial hypercholesterolemia, hypertriglyceridemia
  6. Refsum’s Disease

A. Phytanic Acid
B. Lipoproteins
C. Protein-bound Toxins
D. Immunoglobulins causing hyperviscosity
E. Alloantibodies
F. Immune Complexes

A
  1. F
  2. E
  3. D
  4. C
  5. B
  6. A
72
Q
  • Also referred to as peripheral blood stem cells
  • Can be collected by apheresis from an autologous or allogeneic donor
  • Each procedure lasts 4 to 6 hours
  • Collected by apheresis which involves stimulating the bone marrow and releasing HPCs in the bloodstream using growth factors
  • Collecting is done with a machine
A

Hematopoietic Progenitor Cells

73
Q

Advantages of HPCs

  • ____ is avoided, procedures can be performed in the outpatient setting
A

Anasthesia

74
Q

Advantages of HPCs

T or F: There is a shorter period of cytopenia, decreased transfusion requirements, fewer infectious complications, and decreased length of hospitalization for autologous HPC donors.

75
Q

Adverse Effects of HPCs

  • Complications such as dizziness or fainting can occur especially for donors at higher risks for ____ or ____
A

Presyncopal or syncopal reactions

76
Q
  • Observed during cytapheresis component collections when anticoagulated plasma is returned at a rate
  • Can be clinically detected using Chvostek’s sign or Trousseau’s sign
A

Citrate Toxicity

77
Q

Citrate Toxicity

Twitching of the patient’s muscles when the cheek is tapped

A

Chvostek’s Sign

78
Q

Citrate Toxicity

Spasmodic contraction of muscle in the forearm when blood pressure cuff is inflated

A

Trousseau’s sign

79
Q
  • Large intravenous catheter can lead to bleeding, lung puncture, if the catheter is left in too long, infection may occur
  • Due to catheter insertion or removal
A

Vascular Access

80
Q

Is a fainting episode mediated by the vagus nerve

A

Vasovagal Reactions

81
Q

Vasovagal Reactions

Most common type of fainting

A

Vasovagal Syncope

82
Q

Vasovagal Reactions

Results in a decrease in blood pressure

A

Hypovolemia

83
Q
  • Hypovolemia = IFC
  • Allegic reactions are related to the replacement fluids such as albumin
  • Hemolysis
  • Air embolism and clotting factor deficiencies are not
    commonly observed
A

Miscellaneous Reactions

84
Q

Familiarize yoruself with the prevention and management in plasma procedures

A

● Watch for signs of vasovagal reactions, hypovolemic
reactions, and others
● Ensure adequate fluid replacement to prevent hypovolemia
● Use of appropriate replacement fluids to minimize allergic reactions
● Ensure that patients are suitable for plasmapheresis and monitor them closely.
● Follow and establish protocols to minimize risk
● Monitor and provide supportive care if necessary
● Be prepared to respond to emergency situations such as cardiac arrest and respiratory distress

85
Q
  • Concentration of most plasma substances is
    reduced by 50% to 60% after one standard
    plasmapheresis treatment
  • Removes plasma proteins such as
    immunoglobulins, complements, coagulation
    factors,and lipoproteins
A

Plasma Protein Interactions

86
Q

Major causes of fatalities in apheresis?

A
  1. Circulatory Complications
  2. Respiratory Complications
87
Q

Familiarize yourself with the adverse effects of apheresis.

A

● Citrate toxicity
● Vascular access complications: hematoma, sepsis, phebitis, neuropathy
● Vasovagal reactions
● Hypovolemia
● Allergic reactions
● Hemolysis
● Air embolus
● Depletion of clotting factors
● Circulatory and respiratory distress
● Transfusion-transmitted diseases
● Lymphocyte loss
● Depletion of Proteins and immunoglobulins

88
Q

Match the following.

Timing of Donation/Deferral
1. 48 days/2 days
2. 4 weeks
3. 48 hours
4. 16 weeks

A. Platelet
B. Plasma (occassional)
C. Plasma (serial)
D. Double RBC (autologous allogenic)

89
Q

Match the following.

  1. M = at least 130 lbs, 5’1, 40% HCT
  2. F = at least 150 lbs, 5’5, 40% HCT
  3. Not exceed > 2x per week with normal TP
  4. HES, corticosteroids, or growth factor (GCSF)
  5. Not exceed > 2x per week or 24x per year
  6. PC = 150,000/uL if < 4 weeks interval

A. Platelet
B. Plasma (occassional)
C. Plasma (serial)
D. Double RBC (autologous allogenic)

A
  1. D
  2. D
  3. B
  4. C
  5. A
  6. A